Regeneron sees shares jump on strong 'first read' of US Eylea launch
This article was originally published in Scrip
Executive Summary
Regeneron saw its shares jump in value over 13% after the company told investors and analysts that sales of its recently launched eye drug Eylea (aflibercept) were strong in the fourth quarter – and substantially above the consensus estimate.